Larvol Delta - Ascletis-Announces-First-Participant-Dosed-in-a-Global-Phase-III-Clinical-Program-of-OnceDaily-Oral-Small-Molecule-GLP1-Receptor-Agonist-ASC30-for-Chronic-Weight-Management

ASC30 - Ascletis

https://www.prnewswire.com/news-releases/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-302864376.html

Aug 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next